Related Experiment Videos
[Progressive familial intrahepatic cholestasis (Byler disease): current genetics and therapy]
W Rebhandl1, F X Felberbauer, W D Huber
1Abteilungen für Kinderchirurgie, Medizinischen Fakultät der Universität Wien. Winfried.Rebhandl@akh-wien.ac at
Insights
Progressive familial intrahepatic cholestasis (PFIC) is a serious congenital liver disease impacting children. Surgical interventions like partial biliary diversion (PBD) and liver transplantation (OLT) offer effective treatment options for refractory cases.
Area of Science:
- Hepatology
- Pediatric Gastroenterology
- Medical Genetics
Background:
- Progressive familial intrahepatic cholestasis (PFIC) is a group of rare congenital liver diseases presenting shortly after birth.
- Severe pruritus and progressive liver cirrhosis significantly reduce quality of life and life expectancy in affected children.
- Diagnosis involves clinical, laboratory, and genetic analysis, excluding other causes of intrahepatic cholestasis.
Observation:
- Medical therapy is effective for only a subset of PFIC patients.
- Partial biliary diversion (PBD) is the preferred surgical approach for intractable pruritus.
- Surgical treatment can delay or halt liver damage, potentially avoiding or postponing the need for orthotopic liver transplantation (OLT).
Findings:
- The study provides an overview of PFIC and highlights three surgically treated patients.
- One patient underwent a novel cholecysto-appendicostomy technique for PBD.
- Two patients successfully received OLT for PFIC.
Implications:
- Surgical management, including PBD and OLT, offers viable therapeutic options for PFIC.
- Timely surgical intervention can improve patient outcomes and potentially obviate the need for liver transplantation.
- Further research into novel PBD techniques may enhance treatment efficacy for PFIC.
Abstract:
Progressive familial intrahepatic cholestasis (PFIC) is a congenital liver disease. First symptoms can frequently be seen shortly after birth. Quality and expectation of life are substantially reduced due to severe pruritus and the complications of progressive liver cirrhosis. PFIC is diagnosed on the basis of characteristic clinical and laboratory parameters and genetic analysis after exclusion of other liver diseases leading to intrahepatic cholestasis. Medical therapy is only effective in a proportion of children with PFIC. Partial biliary diversion (PBD) is nowadays considered the therapy of choice in patients with therapy-refractive pruritus. If performed in time, damage to the liver can be delayed or arrested, thus orthotopic liver transplantation (OLT) can be postponed or even avoided in at least some patients with PFIC. Besides providing a current overview of PFIC, we report on three patients who were successfully treated surgically. One patient was subjected to a new technique of PBD (cholecysto-appendicostomy), the other two had OLT.